On March 3, 2023, Aptevo Therapeutics Inc. appointed Jeffrey G. Lamothe, formerly the Company's Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.825 USD | +2.10% | -21.17% | -89.85% |
05-08 | Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | US Equity Markets Close Mixed After March Producer Price Inflation Data | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.85% | 1.3M | |
+7.60% | 113B | |
+11.19% | 106B | |
+0.41% | 22.27B | |
-11.86% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.91% | 17.24B | |
+7.03% | 14.29B | |
+35.73% | 12.52B |
- Stock Market
- Equities
- APVO Stock
- News Aptevo Therapeutics Inc.
- Aptevo Therapeutics Inc. Appoints Jeffrey G. Lamothe to Executive Vice President, Chief Operating Officer